jhe first picentr 5 - accueil | epicentre · a catalyst to stimulate your thinking further on how...
TRANSCRIPT
�.J"he First picentr
. ...
:: ::::::·. ..
:::: :
epi0e ntre +ni.=
:: :rn:EPIDEMIOt.OGIE • EPIDEMIOt.OGY : i' ;;;:
5
994WB£33
These abstracts are not to be quoted for publication 1
Foreword
Welcome to you all!
It is great to see you at the very first Scientific Day Epicentre is organizing in Africa.
Epicentre has provided epidemiological expertise to Médecins sans frontières (MSF) from its Paris headquarters in France for 30 years and has had a base in
Uganda for more than 20 years and in Niger for almost a decade. Epicentre Uganda is located at the heart of Mbarara University of Science and Technology
(MUST) and Mbarara Regional Reference Hospital (MRRH). At this moment we take the opportunity to thank the University leadership and the ministry of
Health that allowed Epicentre to set up a permanent home on its campus from where great work through collaborative effort has been carried out.
Epicentre conducts research and training in support of MSF’s goal of providing medical care in areas where people are affected by conflicts, epidemics,
disasters, or are otherwise excluded from health care. In these contexts medical doctors do not always have tools to respond adequately to the health
needs of the people. Innovation to adapt treatment, diagnostic tools, preventive measures and strategies are needed. These innovations have to be built on
evidence without which no policy advance can take place. This is why Epicentre was created and what it continues to do to this day.
Today we have gathered here as people from different walks of life including politicians, diplomats, academicians, service providers, etc., but for one
common reason; to forge a way for better delivery of health services. As Epicentre, we are proud to share with you research results that we hope will act as
a catalyst to stimulate your thinking further on how to continuously improve health policies and hope to explore with you future research perspectives for
Africa.
In the first session we explore research projects that investigate how HIV care strategies can be adapted and improved. This will be followed by a series on
how tuberculosis treatment can be safely simplified whilst preserving efficacy. The third session will focus on complex emergencies where epidemiological
data need to be made available rapidly in order to mount an effective response. Our last session highlights patients whose needs are neglected despite
great suffering. We hope that this last session will stimulate a discussion on health research topics for Africa today.
At the end of the day we will gather for a drink reception where we can continue to discuss today’s topics informally.
I hope you have an excellent day!
Dr Juliet Mwanga, Director Epicentre Uganda
These abstracts are not to be quoted for publication 2
Programme Serena Hotel. 5th July, 2017
8:00 - 9:00 Registration
Morning programme
9:30 – 10:00 Opening Ceremony
Juliet Mwanga-Amumpaire, Director Epicentre Mbarara Research Centre
Professor Celestino Obua, Vice-chancellor Mbarara University of Science and Technology
Dr Jane Aceng, Minister of Health Uganda
10:00 – 11:00 HIV/AIDS: Research into adapted strategies to improve access to HIV care
Moderator: Dr. Joshua Musinguzi, Program Manager Aids Control Program, Ministry of Health, Uganda
o Understanding virological failure in HIV positive adolescents: is it true treatment failure or poor adherence?
Birgit Schramm
o Fishermen and Fishing communities in East Africa: Most-at-Risk population of acquiring HIV infection. Results from a population-based
survey
Juan Burgos Soto
o Contribution of HIV Population Impact Studies to care strategies : experience of 6 MSF African projects
David Mamano Ongoing project: Lopinavir-based ART for HIVInfected childreNGlobally (LIVING study)
Julian Adong
11:00 – 11:30 Coffee break
These abstracts are not to be quoted for publication 3
o Rifatox: Is it safe to double the dose of rifampicin to shorten tuberculosis treatment duration?
Daniel Atwine
o Rifavirenz: Can high-dose rifampicin be an option to shorten tuberculosis treatment for tuberculosis and HIV co-infected patients?
Maryline Bonnet
o Kids cohort: Pitfalls of childhood tuberculosis diagnosis in high-burden and limited-resource countries.
Elias KumbaKumba
o Ongoing project: TB Speed: Improvement of childhood tuberculosis diagnosis using new technologies for use in low-level health care
facilities.
Eric Wobudeya
12:30-14:00 Lunch
Afternoon programme
14:00 – 15:00 Emergencies and displaced people: research to guide adapted and timely responses
Moderator: Jean-Luc Anglade, Head of Mission Uganda, MSF France
o Nigeria: Borno crisis, mortality and malnutrition in areas of MSF interventionSophie Masson
o Pneumococcal carriage pre- and post-PCV vaccination campaign in Adjumani refugee camp, UgandaDan Nyehangane
o Dihydroartemisinin piperaquine as intermittent preventive treatment for children in refugee campMatthew Coldiron
o Ongoing project: Health assessment and surveillance in refugee camps in Northern UgandaDenis Ardiet
15: 00 – 15:30 Tea break
11:30 – 12:30 Tuberculosis: Optimizing treatment to improve patient outcomes
Moderator: Dr. Frank Mugabe; Program manager NTLP, Ministry of Health, Uganda
These abstracts are not to be quoted for publication 4
17: 00 – 17:30 Closure session
Emmanuel Baron, Director Epicentre, introduces:
Dr. Elioda Tumwesigye: Minister of Science, Technology and Innovation
Juliet Mwanga-Amumpaire closes meeting
17:30 Drinks
15:30 – 17:00 Research off the beaten track: neglected research topics for neglected patients. Perspectives for future research.
Moderator: Philip Guerin, Professor of Epidemiology and Global Health, Oxford University
o Oral cholera vaccines: transforming old products in new solutions for neglected populationsFrancisco Luquero
o PSYCa: Developing a tool to identify young children with mental health problems FabienneNackers
o Efficacy and safety of a new heat stable rotavirus vaccine (ROSE)Amadou Matar Seck
o Antivenoms for snake bites: Combatting market failure and neglect with researchMatthew Coldiron
o Infection control in the era of antibiotic resistanceCéline Langendorf
These abstracts are not to be quoted for publication 5
Understanding virological failure in adolescents living with HIV: Evidence from a cross-sectional assessment and a qualitative study
Birgit Schramm, Epicentre, France
Background
The number of adolescents living with HIV is rising in sub-Saharan Africa, with
this patient group experiencing poor treatment and health outcomes. We
assessed virological failure and drug resistance to first-line antiretroviral therapy
(ART), and qualitatively explored issues influencing adherence amongst
adolescents living with HIV (ALHIV) in Chiradzulu, Malawi.
Methods
A mixed-methods study was conducted between May-November 2016.
Quantitative: A cross-sectional assessment included 10-19 year olds receiving
first-line ART for ≥6 months. Plasma viral load (VL) was assessed and drug
resistance-genotyping performed if VL ≥500 copies/ml. Participants with VL
>1 000 copies/ml received counselling and a second VL test.
Qualitative: We explored individual and social influences on ART adherence
through in-depth interviews with 16 adolescents, 16 caregivers, seven
community members, six health workers, and eight group discussions with
ALHIV and HIV-negative adolescents.
Results
Quantitative: 409 adolescents (median age 13 years, 58% female) participated
after a median of 6.7 years (IQR: 3, 15) on ART (85% AZT-3TC-NVP, 11% TDF-3TC-
EFV). Thirty-two-percent of participants had VL ≥1 000 copies/ml; only 16%
supressed to <1 000 copies/ml after counselling. Resistance testing revealed
80% of virological failures were on ≤1 effective drug. Major resistance included
3TC (86%), NVP (93%) and EFV (75%).
Qualitative: Most adolescents reported difficulties adhering to ART despite
understanding the importance for their health. Adherence was undermined by
individual factors such as poor mental health and inadequate HIV status
disclosure, family factors including precarious caretaking arrangements,
community factors including stigma; and health services factors such as poor
patient-provider relations and overly strict treatment-taking instructions
Conclusions
Treatment failure and drug resistance were high amongst ALHIV in Chiradzulu.
A robust once-per-day first-line regimen and frequent VL monitoring should be
considered to support adherence and minimize accumulation of resistance.
Family-centred approaches are needed alongside youth-friendly health services
with tailored counselling and peer-support clubs to help adolescents thrive on
ART.
Treatment failure is high among HIV-positive adolescents in Chiradzulu. Multiple
social challenges undermine treatment adherence requiring tailored models of
care involving families, peers and communities.
These abstracts are not to be quoted for publication 6
Fishermen and Fishing communities in East Africa: Most-at-Risk population of acquiring HIV infection; Results from a population-based survey
Juan Burgos-Soto, Epicentre, France
Background
In East-Africa, fishing communities are considered HIV most-at-risk population but knowledge about the epidemic in these contexts is scarce. Objective: To estimate the HIV-prevalence rate among adults and children in 12 fishing communities surrounding Lake George and Edward, Uganda; and to assess the HIV cascade of care in these settings.
Methods
We conducted a household-based survey. Trained-nurses visited 890 randomly-selected households interviewing adults of 15-69 years old. Blood samples of HIV-positives were collected for viral load measures. Children <15 years old were eligible for testing only if parents were HIV-positive. Logistic regression models, adjusted on socio-demographic behavioral variables were used to identify factors associated with HIV testing and being HIV-positive, and factors associated with HIV-status unawareness and viral suppression among HIV-positive adults.
Results
Overall, 1 738 adults and 148 children were included. The HIV-prevalence rate among adults was 17.5% (95%CI: 15.8-19.4) and among HIV-exposed children 6.1% (95%CI: 3.1-11.4). HIV-prevalence rate was higher among women (20.9%;95%CI: 18.4-23.5) than among men (13.5%; 95%CI: 11.3-16.1). According
to occupation and sex, farmers had the highest HIV-prevalence rate among women (27.6%) and fishermen among men (18.7%). After adjustment, only fishermen remained with a 4-fold higher risk of being HIV-positive (aOR: 3.9; 95%CI: 1.6-9.4), compared to men of other occupations. Among HIV-negatives, 81.0% declared having had a test in the preceding 12 months. Among HIV-positives, 86.0% declared HIV-status awareness, 78.0% were on ART and 56.0% virally suppressed. Men had a higher risk of being untested than women (aOR: 2.2; 95%CI: 1.4-3.7) and being virally detectable (aOR: 6.6; 95%CI: 1.9-22.0).
Conclusions
HIV-prevalence rate in Ugandan fishing communities is high, particularly among women and fishermen. Although HIV testing and ART initiation rates are high, viral suppression rate remains poor, especially among men. Nevertheless, fishermen do not seem to have a lower access to care than other men. More HIV preventive interventions are needed in these settings, particularly targeting women and fishermen. Strengthening ART-retention, particularly among men, should be a priority in these settings.
HIV-prevalence rate in Ugandan fishing communities is high, particularly among women and fishermen. More HIV preventive interventions are needed as well as strengthening ART-retention, particularly among men
These abstracts are not to be quoted for publication 7
HIV impact in population surveys in Eastern and Southern Africa
David Maman, Epicentre, South Africa
Introduction
To achieve HIV treatment goals, data are needed on the impact of programs. Epicentre has conducted 6 district based population surveys in 5 countries to measure coverage and impact in HIV programs supported by MSF. The results measured progress toward 90-90-90 goals and guided priorities.
Method
A total of six cross-sectional population surveys were implemented in Ndhiwa (Kenya, 2012), Chiradzulu and Nsanje (Malawi, 2013 and 2016, respectively), Eshowe (South Africa, 2013), Gutu (Zimbabwe, 2016), and Kasese (Uganda, 2016). Using multistage cluster sampling, we recruited individuals aged ≥15 years living in 2 400 selected households in Gutu and 2 443 households in Nsanje, and individuals aged 15-69 years living in 828 households in Kasese. Individuals who agreed to participate were interviewed and tested for HIV at home. All participants who tested positive had their viral load measured, regardless of their ART status. In some studies, we also evaluated CD4 counts, HIV incidence as well as transmitted and acquired resistance.
Results
Among 34 386 adults eligible from 15 473 included households, 30 245 (88.0%) were included and tested for HIV+, ranging from 1 738 in Kasese (inclusion 95.9%) to 7 269 in Chiradzulu (inclusion 87.8%).
The overall HIV prevalence ranged from 12.1% (95%CI 11.2-13.0) in Nsanje to 25.2% (95%CI 23.6-26.9) in Eshowe. In each site, the prevalence was higher among men compared to women (p<0.01).
Overall progress toward the 90-90-90 target was: 59/67/83 in Ndhiwa, 77/84/91 in Chiradzulu, 86/94/86 in Gutu, 77/91/89 in Nsanje, and 86/89/68 in Kasese. Each study highlighted that men and HIV-positive individuals younger than 30 were less likely to be diagnosed compared to respectively women or older individuals (p<0.01).
Conclusion
These six surveys, with the exception of the first one conducted in Ndhiwa in 2012, showed overall high coverage and highlighted remaining gaps in the cascade of care. In all sites, coverage outcomes were better among women than men, and among older than younger adults, mostly because they were less likely to be diagnosed. Interventions in these settings should emphasize detection of undiagnosed men and young adults.
We performed population-based surveys in 6 sites in 5 African countries to
evaluate the coverage and impact of HIV programs. In these settings, we showed
that high levels of coverage are achieved. However, detection of undiagnosed
men and young adults needs to be reinforced.
These abstracts are not to be quoted for publication 8
Ongoing project: Lopinavir-based ART for HIV-Infected childreNGlobally (LIVING study)
Julian Adong, Mbarara University of Science and Technology, Uganda
Introduction
The revised WHO treatment guidelines reemphasizes the need to treat all HIV-
infected children below 5 years of age and, and initiate therapy with a
Protease Inhibitor (PI)-based regimen for children less than 3 years of age
regardless of prior exposure to antiretroviral in prevention of mother to child
transmission (PMTCT) programme . Few antiretroviral drugs are approved for
infants and toddlers and existing combination antiretroviral therapies (cARTs)
which typically combine Non-Nucleoside reverse transcriptase inhibitors
(NNRTI) Nevirapine (NVP) and Nucleoside reverse transcriptase (NRTI)
lamivudine (3TC) plus either Abacavir (ABC) or Zidovudine (AZT). They are not
optimal for newly infected infants due to their high viral loads (10 to 100 times
higher than older children); in addition they are often infected with viruses
already resistant to NVP, commonly used for PMTCT. For infants the only
alternative to NVP is the PI, Lopinavir, boosted with ritonavir; however the
available LPV/r liquid formulations for children taste very bitter, are difficult to
administer, and are unstable in tropical climates. This study is evaluating the
effectiveness, safety and acceptability of LPV/r pellets in addition to AZT/3TC
(or ABC/3TC) paediatric fixed dose combination tablet under routine treatment
conditions in HIV infected infants and young children who cannot swallow
tablets.
Methods
It is single arm, open-label, prospective, multicenter, multi-country phase IIIb
study among children with a past or current documentation of a confirmed
diagnosis of HIV-1 infection, eligible for treatment with LPV-based treatment,
weighing ≥3 and <25 kg at the time of enrolment and unable to swallow
tablets. The primary endpoint is treatment effectiveness at 48 weeks based on
a composite endpoint of virologic response <1 000 copies/ml, being alive and
on study drug. Patients are followed-up for 24 months.
Status of study
At the Epicentre site recruitment of participants started on 10th May 2016
and so far 68 patients have been enrolled to date.
Existing combination antiretroviral therapies for children are complex, and not
optimal for newly infected infants with very high viral loads. There is need to
study Lopinavir boosted with ritonavir in pellet form as the available paediatric
liquid formulations have a very bitter taste and are unstable in tropical climates.
These abstracts are not to be quoted for publication 9
Is it safe to double the dose of rifampicin to shorten tuberculosis treatment duration?
Daniel Atwine Epicentre Uganda
Background
The current 6-month TB treatment regimen is still too long. Use of higher doses
of rifampicin(R) might ensure faster lung sterilization with subsequent reduction
in treatment duration. However, R can induce liver toxicity and safety data using
high dose rifampicin are lacking. We assessed whether increasing the dose of
rifampicin (R) from 10 mg/kg to 15 or 20 mg/kg, results in an increase in grade
3 or 4 hepatic adverse events and/or serious adverse events (SAE).
Methods
In a Phase IIB, open-label randomized controlled trial in Bolivia, Peru, and
Uganda, 300 HIV negative patients with newly diagnosed, smear positive, drug
susceptible pulmonary tuberculosis were randomly assigned to one of three
regimens containing ethambutol, isoniazid, rifampicin, and pyrazinamide daily
for 8 weeks followed by isoniazid and rifampicin daily for 18 weeks. The
regimens differed only by the R dose during the first 16 weeks: 1 control regimen
with R at 10mg/Kg and 2 study regimens with R at 15mg/Kg (R15) and 20mg/Kg
(R20). Serum alanine transferase (ALT) measurements were carried out at
regular intervals. Eight week culture conversion was used as surrogate marker
for treatment efficacy.
Results
There were 7 grade 3 increases in ALT levels, 1/100 (1.0%) in R10, 2/100 (2.0%)
in R15 and 4/100 (4.0%) in R20 regimens respectively (trend test p=0.15). R was
discontinued due to liver toxicity in 1 patient (R15). There were no grade 4 ALT
increases. There was a non-significant increase in culture conversion rate with
increasing rifampicin dosage, 75% (69/92) R10, 82.5% (66/80) R15, and 83.1%
(76/91)) R20, (p=0.16).
Conclusions
There was no significant increase in liver toxicity when rifampicin dose increased
from 10mg/kg to 15mg/kg or 20mg/kg.
The use of high-dose rifampicin in shortening of TB treatment duration from 6
months to 3 or 4 months can be possible if its safety is assured. Results of
RIFATOX trial, show no significant increase in drug-induced Liver toxicity even
with doubling of the normal dose of rifampicin.
These abstracts are not to be quoted for publication 10
Can high-dose rifampicin be an option to shorten tuberculosis treatment for tuberculosis and HIV co-infected patients?
Maryline Bonnet, Epicentre, on behalf of IRD UMI 233 TransVIHMI - UM – INSERM U1175, France
Background
Ongoing trials are evaluating high-dose rifampicin (R) regimens to shorten
tuberculosis (TB) treatment duration. The risk of drug interaction with some
antiretroviral precludes the inclusion of HIV-infected patients. We assessed the
effect of high-dose R on the efavirenz (EFV) metabolism in co-infected patients.
Methods
RIFAVIRENZ was a phase-2, randomized, open-label trial conducted in Uganda
between 2014 and 2017. Pulmonary TB and antiretroviral therapy (ART)-naïve
patients were randomized to 2-study regimens (SR) using high-dose R (20mg/Kg)
with ART initiation 2-4 weeks later with 600mg/day (SR1) or 800mg/day (SR2)
EFV; or to 1-control regimen (CR) using R10mg/Kg and EFV600mg/day. At 8
weeks, all patients were switched to standard R and EFV doses. All patients had
intensive pharmacokinetic sampling 4 weeks after EFV-R co-administration, and
4 weeks after R discontinuation. HIV and TB treatment response and safety were
monitored.
Preliminary results
Of 97 included patients (SR1: 31; SR2: 33; CR: 33), 26.8% were females and
median age, weight and CD4 count were 33 years, 53.6 kg and 141 cells/L,
respectively. Under R, the median of the EFV minimum concentration (C24) was
1188, 1064 and 1078ng/mL for SR1 (N=27), SR2 (N=30) and CR (N=28),
respectively. Five (18.5%), 6 (20.0%) and 8 (28.6%) patients had C24 < 750ng/mL.
At 12 weeks post-ART initiation, 92.6%, 86.2% and 92.6% of patients had HIV
viral load < 400 copies/mL. Week 8 TB culture conversion was 88.5% (SR1), 88.9%
(SR2) and 90.3% (CR). During first 8 weeks, 6 (2 per arm) and 4 patients (SR1: 1;
SR2: 2; CR: 1) had transaminase increase > grade 3 and neuropsychiatric events
> grade 2, respectively.
Conclusions
Doubling the R dose does not seem to affect the EFV concentrations. These
preliminary results need confirmation with the comparison of the EFV
pharmacokinetics parameters with and without R.
Trials evaluating high-dose rifampicin short regimens exclude HIV-infected
patients due to risk of drug interaction with antiretroviral. Based on the
preliminary RIFAVIRENZ trial results, doubling the rifampicin dose does not seem
to affect the efavirenz concentrations.
These abstracts are not to be quoted for publication 11
Kids Cohort: Pitfalls of childhood tuberculosis diagnosis in high burden and limited resource settings.
Elias Kumbakumba, Epicentre. Uganda
Background
Diagnosing tuberculosis in children is very challenging, especially in high-burden
resource-limited settings. We report the diagnostic findings of a cohort of
children with clinical suspicion of tuberculosis at the Mbarara Regional Referral
Hospital.
Methods
All children suspected of tuberculosis aged between one month and 14 years
received a comprehensive and standardized clinical and biological evaluation
including XpertMTB/RIF assay and tuberculosis culture and use of induced
sputum in children unable to expectorate. After initial assessment, children with
any positive tuberculosis bacteriological test, chest x-ray or clinical presentation
that were suggestive of tuberculosis disease were started on treatment. Stools
collected from children on treatment were tested with XpertMTB/RIF. At the
end of the study, two independent experts reviewed patients’ files to classify
cases using the 2012 standard case definitions of intra-thoracic tuberculosis.
Results
Of 392 children enrolled, 45.4% were female, 58.1% were younger than 5 years
old, 30.1% were HIV-infected and 19.4% had a tuberculosis contact history
within the last year. Children < 2 years presented more frequently with severe
malnutrition (26.4% vs 5.3%) and were more likely to be diagnosed with a
tuberculosis suggestive chest X-ray (50.8% vs 29.2%) compared to children from
other age groups. A quarter (25.8%) of the children were tuberculin skin test
positive.
Nineteen children (4.8%) were confirmed tuberculosis cases: 18 were either
culture or Xpert positive for MTB on respiratory samples and 1 was positive on
extra-pulmonary sample. Xpert MTB/RIF on stool had a sensitivity of 57.1% and
specificity of 98.2%. Using the standard tuberculosis case definitions, a total of
58/373 (15.4%) children were classified as confirmed or probable tuberculosis.
In total, 144 (36.7%) were started on treatment.
Conclusion
This study confirms the difficulties with diagnosing childhood tuberculosis. The
majority of cases were diagnosed without confirmation of tuberculosis despite
the use of exhaustive diagnostic tests and optimised specimen collection. Rapid,
non-sputum based and highly sensitive tests are still needed for diagnosis of
childhood tuberculosis. Meanwhile, every opportunity should be taken to
improve tuberculosis diagnosis especially among children presenting with
severe clinical conditions.
These abstracts are not to be quoted for publication 12
TB Speed: Improvement of childhood tuberculosis diagnosis using new technologies for use in low-level health care facilities.
Eric Wobudeya, MUJHU care ltd & Mulago National Referral hospital, Uganda
Background
Notification of tuberculosis in children is still low. This likely to be due to the
paucibacillary nature of childhood tuberculosis, the difficulty to obtain sputum,
the low diagnostic yield of existing tests, weak chest radiograph services, lack of
systematic screening at all health facility entry points, and absence of point-of-
care tests. Improved case detection and access to treatment for children with
tuberculosis is a key step to reach the goal of zero death from tuberculosis.
Objective
The TB-SPEED project goal is to contribute to the reduction in childhood
mortality from tuberculosis by delivering an available, feasible, cost-effective,
and decentralized childhood tuberculosis diagnostic approach to enhance case-
finding and access to treatment.
Project implementation plan
This is a four-year UNITAID-funded project implemented in seven countries
(Cambodia, Cameroon, Côte d’Ivoire, Mozambique, Sierra Leone, Uganda, and
Zambia) to start in September 2017 with three major patient-centred outputs
and three technical support outputs building evidence for future scale-up.
The project will innovatively validate a decentralized diagnostic approach using
battery-operated GeneXpert OMNI and Xpert ultra cartridge to increase access
to tuberculosis diagnostics. It also proposes a simplified nasopharyngeal
aspirate sample collection method through the use of battery-operated suction
machines that are suitable for rural areas. The project also aims to optimize stool
processing without centrifugation allowing stool Xpert testing at lower-level
health care facilities. The approach will also include optimized screening, clinical
and radiological diagnosis through training, mentorship, the use of digital
radiography, and establishment of quality control of X-ray reading.
Project outputs
1. New decentralized childhood tuberculosis diagnostic approaches tested at
district health system level
2. Evaluation of an early tuberculosis detection strategy in children with
severe pneumonia
3. Validation of diagnostic tools and algorithms in highly vulnerable groups
with presumptive tuberculosis, specifically HIV-infected and severely
malnourished children
4. Identification of optimized, suitable, and affordable specimen collection
and processing methods for childhood tuberculosis diagnosis in
resource-limited countries
5. Evaluation of cost-effectiveness of the proposed diagnostic approaches
6. Dissemination, communication and stakeholders’ engagement
The TB-SPEED project aims to increase case detection and reduce
mortality of children with tuberculosis through decentralization of diagnosis systematic and screening for tuberculosis of children with HIV infection severe
malnutrition, or severe pneumonia.
These abstracts are not to be quoted for publication 13
Borno crisis, Nigeria. Mortality and nutrition in areas of MSF intervention
Sophie Masson, Epicentre, France
Background
Since 2013, the Boko Haram insurgency and military operations have led to mass
population displacement in northeastern Nigeria. From June 2016, MSF was able
to operate inside and to lesser extend outside of Maiduguri. We present a series
of surveys and surveillance results between July 2016 and May 2017, to describe
the health and nutrition status of the population and follow the situation over
time.
Methods
In Banki camp, 4 retrospective mortality surveys, using systematic sampling
were undertaken between July and December 2016, coupled with malnutrition
assessments. In Maiduguri, prospective surveillance of mortality, population
size, and malnutrition was carried out in 12 camps in 2016. Retrospective
mortality surveys and nutritional assessments were carried out in two unofficial
camps between September and October 2016, using exhaustive and systematic
sampling. A survey using spatial sampling covering the urban area of
Maiduguriexcluding campswas carried out in November 2016. Cross-
sectional population based surveys using spatial cluster sampling were carried
out in the catchment areas of MSF nutrition programme to estimate prevalence
of malnutrition and programme coverage in May 2017.
Results
In Banki, the initial retrospective mortality and rapid malnutrition screening in
July 2016 demonstrated an extremely critical situation. The subsequent surveys
showed a rapid decrease of both mortality and malnutrition. The surveys in the
two unofficial camps in Maiduguri were also indicative of a critical situation,
while the survey of the overall urban areas showed low mortality and
malnutrition for both host community and internal displaced people in the
community. The surveys in the Maiduguri MSF ambulatory treatment feeding
centre’s (ATFC) catchment areas showed low prevalence of malnutrition.
Nevertheless, admissions to ATFCs remained very high.
Conclusion
The situation in camps assessed outside of Maiduguri were critical, but showed
a rapid improvement, despite challenges of accessibility. In Maiduguri, where
accessibility to and from the population is less challenging, Overall indicators
were much better but there remained pockets of vulnerability”. The high
number of patients presenting to services is better explained by a large number
of people in the area rather than by high prevalence or good coverage.
Following mass displacement of population in Borno state, Nigeria, and
subsequent MSF emergency response, various retrospective mortality surveys
and rapid nutritional assessments were carried out in order to describe and
follow over time the extent of the crisis and its evolution in the areas of MSF
intervention. Evaluation of dense urban areas remains a challenge.
These abstracts are not to be quoted for publication 14
Pneumococcal carriage and serotypes distribution pre- and post- PCV vaccination campaign in Adjumani refugee camps, Uganda
Dan Nyehangane, Epicentre, Uganda
Background
In July-September 2014, MSF conducted a mass vaccination campaign (MVC)
among children aged between 6 weeks and 23 months in Adjunami settlements
using pneumococcal conjugate (PCV-10) vaccines. We aimed to examine the
impact of the MVC on pneumococcal carriage and serotypes circulation.
Methods
Three nasopharyngeal (NP) pneumococcal carriage household surveys
(respectively in July 2014, March and June 2015) were carried out among
residents (all ages). Streptococcus pneumoniae was cultured from NP swab
specimens. All pneumococcal isolated were serotyped using the Quellung
method in Epicentre Mbarara-Uganda Laboratory, in order to describe
pneumococcal serotyping distribution in Adjumani population before and after
the PCV mass vaccination campaign. In addition, MSF conducted a vaccination
coverage cluster survey among children aged between 6 weeks and 23 months
in October 2014.
Results
Among children in the age range for vaccination, 96% (95%CI 94-98%) received
at least one dose of PCV-10 and 43% (95%CI 39-47%) received 3 doses of PCV-
10. Overall pneumococcal carriage increased from 58% (95%CI 56-61%) in the
first survey to 67% (95%CI 64-69%) in the third, and from 86% (95%CI 83-90%)
to 92% (95%CI 90-94%) among children younger than 24 months. Vaccines
serotypes decreased from 37% (95%CI 34 – 40%) to 15% (95%CI 14-18%) overall,
and from 49% (95%CI 44-54%) to 17% (95%CI 14-21%) among children less than
24 months.
Conclusion
Following the PCV-10 mass vaccination campaign, NP carriage increased. A
significant and rapid replacement of vaccines serotypes by non-vaccines
serotypes was observed in all age groups, including non-vaccinated age-groups.
Non-vaccines serotypes are expected to be less invasive. Improvement of
surveillance of invasive pneumococcal disease is required, together with
serotypes circulating in order to monitor the impact of PCV mass vaccination.
Nasopharyngeal pneumococcal carriage increased among the overall population
of Adjumani settlements, following a PCV-10 mass vaccination campaign
organized between July and September 2014. A significant and rapid
replacement of vaccines serotypes by non-vaccine serotypes was observed in all
age groups, including non-vaccinated age-groups.
These abstracts are not to be quoted for publication 15
Dihydroartemisinin-piperaquine as intermittent preventive treatment for children in refugee camp
Matthew Coldiron, Epicentre, France
Background
Northern Uganda hosts a large population of refugees from South Sudan, and
malaria is one of the major health problems in the area. In 2015, intermittent
preventive treatment for malaria (IPTc) was implemented in two refugee
camps among children aged six months to 14 years.
Methods
Three distributions of dihydroartemisinin-piperaquine (DP) were conducted at
eight-week intervals. The first dose was directly administered at IPTc
distribution sites and the second and third doses were given to caregivers to
administer at home. A multi-faceted evaluation was implemented, including
coverage surveys, malaria prevalence surveys, reinforced surveillance, and
pharmacovigilance.
Results
Programme coverage exceeded 90% during all three distributions with a total
of 40 611 participants. Compared to same period during the previous year
(only available data), the incidence of malaria in the target populations was
reduced (IRR 0.73, 95% CI 0.69-0.77 among children under five years old; IRR
0.70, 95% CI 0.67-0.72 among children aged five-14 years). Among those not
targeted for intervention, the incidence between the two years increased (IRR
1.49, 95% CI 1.42-1.56). During the intervention, estimates of the prevalence
of parasitemia (by microscopy or PCR) ranged between 12.9-16.4%, with the
highest prevalence among children aged five-14 years. This increased to 25.3%
(95% CI 22.1-28.8) eight weeks after the final distribution. A total of 57 adverse
events were reported during the intervention period, including 1 severe
adverse event (death from varicella). Adverse events were of mild to moderate
severity, and were mainly dermatologic and gastrointestinal.
Conclusion
This is the first documentation of an IPTc programme in a refugee camp. The
positive impact of DP on the incidence of malaria, together with its favourable
safety profile, should lead to further use of IPTc in similar settings. Expanding
coverage groups and decreasing intervals between distributions might provide
more benefit, but would need to be balanced with the operational implications
of a broader, more frequent distribution schedule.
Preventing malaria in vulnerable populations is a major challenge. The use of
DHA-Piperaquine was an effective and safe strategy for intermittent preventive
treatment in Uganda
These abstracts are not to be quoted for publication 16
Health assessment and surveillance in refugee camps in Northern Uganda
Denis Ardiet, Epicentre, Paris
Background
Following escalation of violence in South Sudan in July 2016, thousands of
refugees crossed the border with Uganda. The Ugandan government settled
them into the Bidibidi, and subsequently also the Imvepi settlement. Because
they were highly dependent on humanitarian aid, a baseline health and
mortality survey assessed their health status. This was followed by the
implementation of two different health surveillance systems allowing weekly
reporting of most basic health indicators.
Methods
Households were randomly selected by spatial sampling, and household
structures were assessed. Nutrition status for children <5 years was evaluated
using Mid-Upper Arm Circumference (MUAC) and edema assessment.
Retrospective mortality used a 5-months recall period. Two different weekly
surveillance systems were implemented, one following the Ugandan community
health system and another “lighter” system, focusing on mortality and most
epidemic diseases. A second survey was performed for new arrivals to collect
more information about mortality in South Sudan and during their journey.
Results
A total of 1 018 heads of household accepted to participate in the baseline
survey. The population was found to be very young, and split households were
frequent with 20% of that population missing; 32% of households were headed
by women. Many households also lacked crucial non-food items. In the
settlements, malnutrition and mortality appeared to be below emergency
thresholds but delays in food distribution were frequent. On the other hand,
crude mortality rates were found to be high in South Sudan with many violent
deaths recorded. Surveillance systems revealed small bursts of bloody diarrhea
and malnutrition pockets in both settlements.
Conclusions
Our assessments reflected high levels of violence in South Sudan. In the Uganda
settlements, health indicators were under control but still need to be
monitored.
Health assessment and surveillance among South Sudanese refugees are
essential activities, as access to food, water and health services remains fragile.
Research off the beaten track:
neglected research topics for neglected patients.
Perspectives for future research
Session 4
These abstracts are not to be quoted for publication
17
Oral cholera vaccines: transforming old products into new solutions for neglected populations
Francisco Luquero, Epicentre, Switzerland
Cholera vaccines have only recently become a control tool despite the fact that
early prototypes of the currently prequalified cholera vaccines exist since the
1880s. Key research conducted by Médecins Sans Frontières and Epicentre has
shown that mass campaigns using oral cholera vaccines (OCV) are feasible in
different settings (humanitarian crises, outbreaks and endemic countries), well
accepted by the population, and that the vaccines are a safe and effective tool
for prevention and response. In addition, we recently demonstrated that short-
term vaccine protection can be achieved with a single dose of vaccine, which is
a major logistical advantage in response to outbreaks. These key data, along
with the creation of a global stockpile managed by the WHO and dedicated
funding have led to the doubling of the number of OCV doses delivered
worldwide each year since 2012.
However, the significant public health benefit from OCV has not yet been
realized because of cost, availability (supply) and logistical constraints. These
include a recommendation for two doses, with the second delivered 14 days
after the first, high packing volume and cold chain requirements. These factors
make vaccine delivery costly and challenging in certain settings. In addition, the
complex vaccine formulation translates in suboptimal production, which limits
vaccine availability and impedes price reduction (~1.85USD per dose), making
the total cost of one fully vaccinated person approximately 6USD.
An improved new generation cholera vaccine could lift these barriers and will
bring substantial public health benefits. Any new vaccine should be easier to
produce, cheaper, heat-stable and have a reduced storage volume. As one of
the main responders to cholera epidemics, MSF could play an important role in
pushing for improved vaccines. With better cholera vaccines, used in
conjunction with WaSH measures, many more lives could be saved and perhaps
the elimination of cholera outbreaks could be foreseen in a near future.
The potential impact of cholera vaccine has not fully materialized because of
limitations of current products. New vaccines should be easier to produce,
cheaper, heat-stable and with reduced storage volume. MSF and Epicentre
could play an important role in pushing for such improved vaccines.
These abstracts are not to be quoted for publication 18
PSYCa: Developing a tool to identify young children with mental health problems
Fabienne Nackers, Epicentre, Belgium
Background
In low-resource settings, the lack of mental health human resources and the
absence of cross-culturally validated screening instruments jeopardize the
implementation of mental health care, especially for very young children. We
aimed to develop and validate a cross-cultural general tool, the PSYCa 6-36, to
screen for psychological difficulties in children aged 6 to 36 months.
Methods
A primary validation of the PSYCa 6-36 was conducted in Kenya (n=319 children
aged 6 to 36 months; 2014), followed by three secondary validations (n=215,
Kenya, 2014; n=189, Cambodia, 2015; n=182, Uganda, 2016). After standardized
translation procedures, lay interviewers administrated the PSYCa 6-36 in local
languages to the children’s caregivers at home. We assessed the psychometric
properties of the tool and its external validity against a gold standard (i.e. clinical
global impression severity [CGIS] score rated by a psychologist after clinical
assessment).
Results
The internal consistency of the PSYCa 6-36 was acceptable (Cronbach’s alpha
ranged from 0.61 to 0.74) and its temporal reliability was very good (intra-class
correlation coefficient [ICC] ≥0.80). The inter-rater reliability was acceptable to
good (ICC ranged from 0.60 to 0.83) as well as the external validity (area under
the curve ranged from 0.63 to 0.80). The prevalence of CGIS scores ≥1, indicating
mental health difficulties according to the psychologist, was 5.1% in Kenya, 8.7%
in Cambodia and 10.5% in Uganda.
Conclusion
The results of this study show that the PSYCa 6-36 is a promising screening tool
for young children. Once adapted to the local context, the PSYCa 6-36 was easy
and quick to use for trained non-specialists. The PSYCa 6-36 also increased the
awareness on children’s psychological difficulties and the importance of early
recognition to prevent long-term consequences. Further use and validation of
the tool in settings with higher prevalence of psychological difficulties will help
to refine the scale.
The PSYCa 6-36 is a useful tool to screen for psychological difficulties among
children aged 6 to 36 months.
These abstracts are not to be quoted for publication 19
Efficacy and safety of a new heat stable rotavirus vaccine (ROSE)
Amadou Matar Seck , Epicentre, Niger
Background
Every year, rotavirus gastroenteritis causes about one-third of deaths due to
diarrhea among children under 5 worldwide, most of which occur in sub-
Saharan Africa. Infection can be prevented with a vaccine, but a global
shortage of the vaccine and the need for cold-chain transport presents delivery
challenges.
Methods
We conducted a double-blind, randomized, controlled trial in Niger to evaluate
the efficacy and safety of BRV-PV (Serum Institute of India, Pvt Limited), a live,
oral, heat-stable rotavirus vaccine. Healthy infants received three doses of
vaccine or placebo at 6, 10, and 14 weeks of age. Episodes of gastroenteritis
were assessed through active and passive surveillance. The primary endpoint
was vaccine efficacy from 28 days post-dose 3. Assuming a 2% attack rate, a
50% true vaccine efficacy, and 20% participant non-assessibility, 117 cases (78
unvaccinated and 39 vaccinated) were required to establish 50% true vaccine
efficacy. All serious adverse events, including intussusception, and adverse
events were assessed using facility- and home-based surveillance.
Results
Among the 3 508 infants included in the per-protocol efficacy analysis (1 780 in
the vaccine group and 1 728 in the placebo group), there were 31 and 87 cases
of severe rotavirus gastroenteritis in the vaccine and placebo groups,
respectively (2.14 and 6.44 cases per 100 person-years), resulting in a vaccine
efficacy of 66.7% (95%CI 49.9–77.9). Similar efficacy was seen in the intention-
to-treat analyses. There was no difference in the risk of adverse events (68.7%
vaccine and 67.2% placebo) or serious adverse events (8.3% vaccine and 9.1%
placebo), including death (n=27 vaccine and n=22 placebo). No child had
confirmed intussusception.
Conclusion
We found BRV-PV to protect against severe rotavirus gastroenteritis among
infants. BRV-PV does not require refrigeration and represents an important
option to prevent morbidity and mortality among the most vulnerable
Rotavirus gastroenteritis leads to about one-third of diarrheal disease deaths in
children. We found BRV-PV to protect against severe rotavirus gastroenteritis
among infants in Niger
These abstracts are not to be quoted for publication 20
Antivenoms for snake bites: Combatting market failure and neglect with research
Matthew Coldiron, Epicentre, France
Venomous snakes are widely distributed, but most snakebites occur in rural
areas of the tropics. Although data are notoriously poor, in Africa, there are an
estimated 1 million snakebites, 500 000 envenomings, and up to 30 000 deaths
annually.
The venom of any single snake may contain more than 100 different toxins and
enzymes, so the clinical result for victims can differ as well. Three major
families of toxicities exist: local cytotoxicity (tissue necrosis), neurotoxicity
(paralysis), and hematotoxicity (pro-coagulant and anti-coagulant).
Snakebite patients with evidence of envenoming should be promptly treated
with antivenom. The choice of antivenom depends on the local epidemiology
of snakebites and the availability of antivenoms. If given with minimal delay,
antivenoms can drastically reduce mortality associated with snakebite,
particularly for hematotoxic envenomings, which typically cause death many
hours or days after the snakebite.
Antivenom production is onerous and has changed little since the 19th century.
In brief, venom is harvested from snakes and small amounts are injected into a
mammal (usually horses). After several months, the equine serum is collected
and purified, and anti-venom specific antibodies are collected, and sometimes
digested into fragments. Some commercially available antivenoms are species-
specific, others are polyvalent.
FAV-Africa (Sanofi Pasteur) is a polyspecific antivenom which covers 10
different species of snakes. It has been the primary antivenom used by MSF
across Africa for many years. Its production ended in 2013, and the last doses
produced expired in June 2016. Several new antivenoms have entered the
market in recent years, but with insufficient data supporting their safety and
efficacy. In several settings, MSF is facing challenges over the choice of
antivenom (or antivenoms) to use to replace FAV-Africa. Epicentre is
conducting studies in the Central African Republic and South Sudan to evaluate
and document the use of new products.
Snakebite is a major health problem in rural Africa. Although there are several
antivenoms available, there is insufficient data to support their safety and
efficacy.
These abstracts are not to be quoted for publication 21
Infection control in the era of antibiotic resistance
Céline Langendorf, Epicentre, France
Prescribing antibiotics without considering the risk of resistance is no longer
possible today. First, antibiotic resistance is rising to high levels across the world,
threatening ability to treat infectious diseases, even the most common ones.
Second, antibiotic resistance is accelerated by the misuse of antibiotics and poor
infection prevention and control.
In hospitals and community settings, ongoing research takes a holistic approach
by addressing different aspects: diagnosis, treatment and prevention. We are
conducting several descriptive studies with the objective of filling in data gaps
on the etiologies of bacterial infections, antibiotic resistance and to adapt
therapeutic protocols.
The presentation will be based on, first, several etiology studies in children in
sub-Saharan Africa; and next on documentation of how antibiotic are
prescribed. This provides an insight into gaps and opportunities to improve
antibiotic formulation, especially in pediatrics. The use of antibiotic prophylaxis
can increase the transmission of multi-drug resistant organisms within the
community. Finally, research on infection prevention and control and antibiotic
resistance is essential to improve the treatment protocols and reduce the
impact and spread of resistance
Antibiotic resistance is rising to high levels across the world, threatening ability
to treat infectious diseases. We discuss how research on infection prevention
and control and antibiotic resistance can help improve the treatment protocols
while reducing the spread of resistance.
Epicentre 8 rue Saint Sabin
75011 Paris France
Tel : +33 1 40 21 55 55
Epicentre Mbarara Research CentreP.O Box 1956
MbararaUganda
Email: [email protected]
www.epicentre.msf.org